• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[CD19嵌合抗原受体T细胞疗法的白细胞单采临床经验]

[Clinical experience of leukapheresis for CD19 CAR-T cell therapy].

作者信息

Jo Tomoyasu, Yoshihara Satoru, Arai Yasuyuki, Ikemoto Junko, Onomoto Hitomi, Sugiyama Hiroki, Yoshihara Kyoko, Matsui Keiko, Niwa Norimi, Nakagawa Yoko, Kitawaki Toshio, Kanda Junya, Takaori-Kondo Akifumi, Nagao Miki

机构信息

Department of Clinical Laboratory Medicine and Center for Research and Application of Cellular Therapy, Kyoto University Hospital.

Department of Hematology and Oncology, Kyoto University Hospital.

出版信息

Rinsho Ketsueki. 2021;62(3):163-169. doi: 10.11406/rinketsu.62.163.

DOI:10.11406/rinketsu.62.163
PMID:33828008
Abstract

To perform chimeric antigen receptor T (CAR-T) cell therapy in heavily pretreated patients with progressive disease and depleted lymphocytes, an optimized leukapheresis protocol must be established. To probe the effects of patient-related parameters on the collection efficiency of CD3 cells, we retrospectively analyzed patients with relapsed/refractory diffuse large B-cell lymphoma who underwent leukapheresis for tisagenlecleucel at two centers. A total of 51 patients were analyzed, with a median age at apheresis of 59 years, and precollection hemoglobin levels, CD3 cell counts, and platelet counts of 9.2 g/dl, 574/µl, and 15.8×10/µl, respectively. A median of 3.0×10 (0.7-8.4) CD3 cells were harvested with 8.7 (4.0-15.7) l apheresis volume. The collection efficiency 2 (CE2) for CD3 cells was 61.0% (21.0-127.3). One-day apheresis was sufficient to obtain the designated cell numbers in all cases. Lower hemoglobin levels, higher CD3 cell counts, and higher platelet counts before apheresis were significantly associated with lower CE2 for CD3 cells. These results suggest a need to increase the apheresis volume in anemic, lymphocyte- or platelet-rich patients due to an expected low CE2. Erythrocyte transfusions before or during apheresis may be a reasonable option for patients with anemia.

摘要

对于病情进展且淋巴细胞耗竭的经大量预处理的患者进行嵌合抗原受体T(CAR-T)细胞治疗时,必须建立优化的白细胞分离方案。为了探究患者相关参数对CD3细胞采集效率的影响,我们回顾性分析了在两个中心接受替沙格韦单抗白细胞分离术的复发/难治性弥漫性大B细胞淋巴瘤患者。共分析了51例患者,采血时的中位年龄为59岁,采集前血红蛋白水平、CD3细胞计数和血小板计数分别为9.2 g/dl、574/µl和15.8×10/µl。中位采集量为8.7(4.0 - 15.7)升,收获3.0×10(0.7 - 8.4)个CD3细胞。CD3细胞的采集效率2(CE2)为61.0%(21.0 - 127.3)。在所有病例中,单日白细胞分离术足以获得指定的细胞数量。采集前血红蛋白水平较低、CD3细胞计数较高和血小板计数较高与CD3细胞的CE2较低显著相关。这些结果表明,由于预期采集效率较低,对于贫血、淋巴细胞或血小板丰富的患者需要增加白细胞分离量。在白细胞分离术前或术中进行红细胞输血可能是贫血患者的合理选择。

相似文献

1
[Clinical experience of leukapheresis for CD19 CAR-T cell therapy].[CD19嵌合抗原受体T细胞疗法的白细胞单采临床经验]
Rinsho Ketsueki. 2021;62(3):163-169. doi: 10.11406/rinketsu.62.163.
2
A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy.一种临床适用的预测模型,可提高嵌合抗原受体 T 细胞治疗中的 T 细胞采集。
Transplant Cell Ther. 2022 Jul;28(7):365.e1-365.e7. doi: 10.1016/j.jtct.2022.04.013. Epub 2022 Apr 20.
3
Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.为复发/难治性 NHL 或 ALL 患者制造 CAR-T 细胞提供优质白细胞去除产品的当前挑战。
Cells. 2020 May 15;9(5):1225. doi: 10.3390/cells9051225.
4
T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.在外周血白细胞分离时的 T 细胞计数可预测随后 CAR-T 细胞治疗的反应。
Sci Rep. 2022 Nov 4;12(1):18696. doi: 10.1038/s41598-022-23589-9.
5
Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.在接受 CAR 转导的白细胞分离产物中鉴定双阳性 CD19+/CD3+ T 细胞:病例报告。
J Immunother Cancer. 2020 Sep;8(2). doi: 10.1136/jitc-2020-001073.
6
Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients.在经过大量预处理的儿科患者中进行白细胞分离术以生产 CAR T 细胞的可行性。
Transfus Apher Sci. 2020 Aug;59(4):102769. doi: 10.1016/j.transci.2020.102769. Epub 2020 Apr 25.
7
Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.用于白血病和神经母细胞瘤儿童及青年嵌合抗原受体T细胞制造的淋巴细胞单采术
Transfusion. 2018 Jun;58(6):1414-1420. doi: 10.1111/trf.14569. Epub 2018 Mar 13.
8
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.白细胞分离术指导与嵌合抗原受体 T 细胞最优生产的最佳实践
Cytotherapy. 2022 Sep;24(9):869-878. doi: 10.1016/j.jcyt.2022.05.003. Epub 2022 Jun 17.
9
Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients.用于成年淋巴瘤患者嵌合抗原受体T细胞生产的血细胞分离术
Transfusion. 2022 Aug;62(8):1602-1611. doi: 10.1111/trf.17030. Epub 2022 Jul 19.
10
Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.3 岁以下复发/难治性急性淋巴细胞白血病患者的白细胞去除术和 Tisagenlecleucel 生产结果。
Transplant Cell Ther. 2023 Sep;29(9):579.e1-579.e10. doi: 10.1016/j.jtct.2023.06.007. Epub 2023 Jun 11.

引用本文的文献

1
T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.在外周血白细胞分离时的 T 细胞计数可预测随后 CAR-T 细胞治疗的反应。
Sci Rep. 2022 Nov 4;12(1):18696. doi: 10.1038/s41598-022-23589-9.